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Colorectal cancer (CRC) is the second most common cause of
cancer death in the Western world. 5-year survival is poor ranging
from 40 to 60% (Office for National Statistics, 1999). However
25% of patients present with metastatic disease with dismal
outcome and ultimately 50% of patients will die of locally
advanced or metastatic disease. Protracted intravenous infusion
(PVI) of 5 fluorouracil (5-FU) produced a modest response rate in
patients who were chemonaive (30%) (Lokich et al, 1989) or resis-
tant to bolus 5-FU (22%) (Lokich et al, 1983). Continuous infu-
sion of 5-FU has shown a small but statistically significant
survival advantage over bolus protocol in a recent meta-analysis
(The Advanced Colorectal Cancer Meta-Analysis Project, 1998)
and has been the mainstay salvage treatment for bolus 5-FU resis-
tant colorectal carcinoma patients until recently. Oxaliplatin is a
novel platinum compound with promising results in first-line
treatment for metastatic colorectal carcinoma in combination
with fluoropyrimidines. 2 randomised trials in untreated patients
with advanced colorectal carcinoma have shown superior
response with combination of oxaliplatin and 5-FU/leucovorin
(LV) over the same schedule of 5-FU/LV (de Gramont et al,
2000; Giacchetti et al, 2000). Both of these trials have also shown
a significant progression-free survival benefit with oxaliplatin but
no overall survival advantage. However, a large proportion of
patients in the 5-FU/LV alone arm crossed over to oxaliplatin
salvage or received irinotecan, which is a proven effective second-
line treatment (Cunningham et al, 1998; Rougier et al, 1998).
Since it is likely that patients have few symptoms prior to tumour
progression, progression-free survival would probably be an
adequate surrogate marker of the true clinical benefit derived from
oxaliplatin. Neither of these trials reported on the symptoms
patients experienced before, during or after chemotherapy, there-
fore no direct evidence of palliative effect on patients’ symptoms
can be obtained. Although quality of life (QoL) data were reported
in one trial (de Gramont et al, 2000), no definite advantage was
seen with oxaliplatin (only time to deterioration of the global
health status was significantly prolonged in the oxaliplatin arm).
However, no deterioration in QoL was seen despite higher inci-
dences of toxicity associated with oxaliplatin over 5-FU/LV alone.
This is likely to reflect oxaliplatin’s positive impact on tumour-
related symptoms. 
Oxaliplatin and 5-FU have also been tested in a number of
second-line studies in advanced colorectal carcinoma (Machover
et al, 1996; Andre et al, 1998, 1999; Brienza et al, 1999;
Maindrault-Goebel et al, 1999, 2001; Adenis et al, 2000; Martoni
et al, 2001). No randomised phase III trials have yet been
published in full, therefore no conclusions can be drawn from them
although the preliminary data do look promising (Adenis et al, 2000).
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Summary The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI
5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer. 38 patients with advanced or metastatic colorectal carcinoma
with documented progression on or within 6 months following 5-FU or thymidylate synthase inhibitor containing chemotherapy were recruited
between June 1997 and September 2000. Oxaliplatin (100 mg m–2) was given every 2 weeks and PVI 5-FU (300 mg m–2 day–1) was
administered. Median age of patients was 61 years. 17 patients had >2 sites of disease involvement. 10 had received 5-FU based adjuvant
chemotherapy. 16 received oxaliplatin and PVI 5-FU as second-line chemotherapy for advanced disease and 22 as third or subsequent lines.
Median follow up was 6.1 months. The best achieved objective tumour response rate was 29% (11 partial responses 95% confidence interval
[CI] = 15–46%). 20 patients (52.6%) had stable disease. The median duration of response was 3.9 months. Even for patients who had
previously received both 5-FU and irinotecan (n = 22), 27.3% had partial response with oxaliplatin and PVI 5-FU. 37 patients had symptoms
on entry into the study. 25 patients had pain, 10 had anorexia and 28 had lethargy. 64%, 70% and 17.9% had symptomatic improvement after
treatment respectively. Grade 3–4 toxicities were anaemia 10.6%, neutropenia 2.6%, thrombocytopenia 5.2%, diarrhoea 18.9%, nausea and
vomiting 2.7%, infection 5.4% and lethargy 37.8%. The median survival was 9.1 months. Probability of overall survival at 6 months was 58.4%
(95% CI = 38.7–73.7%). The median failure-free survival was 4 months. Oxaliplatin and PVI 5FU is an active and well tolerated regimen in
patients with heavily pre-treated advanced colorectal cancer. © 2001 Cancer Research Campaign 
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The safety and efficacy of a variety of dosing regimens with 5-FU
and leucovorin and oxaliplatin have been evaluated and the combina-
tion has demonstrated marked antitumour efficacy (Levi et al, 1994,
1997, 1999; Machover et al, 1996; Andre et al, 1998, 1999; Gramont
et al., 1997, 2000; Giacchetti et al, 2000). Oxaliplatin and PVI 5-FU
(OXAF), however, has not been extensively explored and we have
therefore investigated this combination using a 2 weekly schedule
of oxaliplatin in 5-FU resistant patients. 
Prior to the commencement of our study, FOLFOX 2 regimen
was reported with a response rate of 46% and a median progres-
sion-free survival of 7 months in patients who progressed while on
leucovorin and 5-FU therapy (de Gramont et al, 1997). This 2-
weekly regimen consisted of oxaliplatin 100 mg m–2 as a 2-hour
infusion on day 1, leucovorin 500 mg m–2 day–1 as a 2-hour infu-
sion followed by a 24-hour infusion of 5-FU at 1500–2000 mg m–2
day–1 for 2 consecutive days. Based on the encouraging results
from FOLFOX 2, biweekly oxaliplatin at a dose of 100 mg m–2
was adopted in our study. 
PATIENTS AND METHOD 
We conducted a phase II open-labelled study between June 1997
and September 2000. This study was approved by the local
biomedical ethics committees. A signed, written informed consent
was obtained from each patient. 
Eligibility criteria 
Admission criteria were: histologically proven advanced or
metastatic inoperable adenocarcinoma of the colon or rectum;
documented progression during or within 6 months following
fluoropyrimidine or thymidylate synthase inhibitor containing
chemotherapy for advanced disease or during 5-FU based adjuvant
treatment; bidimensionally measurable disease on chest X-ray or
computer tomography (CT scan) outside any previous irradiated
zone; ECOG performance status 0–2; absence of severe neuropathy
(> grade 1 according to National Cancer Institute-Common
Toxicity Criteria (Macdonald et al, 1995)) and no central nervous
system disease. Baseline criteria of blood analyses were as
follows: white blood count >3 × 109 l–1, neutrophil > 1.5 × 109 l–1
and platelet > 100 × 109 l–1, bilirubin <30 µ mol l–1, creatinine <180
µ mol l–1. Before entry into the study, all patients were required to
have chest X-ray, CT scan of chest, abdomen and pelvis and carci-
noembryonic antigen (CEA) measurement. 
Chemotherapy regimen 
Oxaliplatin (100 mg m–2) was delivered as an intravenous infusion
over 2 hours. This was repeated every 2 weeks unless there were
significant toxicities (one cycle). No pre- or post-chemotherapy
hydration was required for oxaliplatin administration. 5-FU
(300 mg m–2 day–1) was administered as a continuous infusion via
a central venous catheter (Hickman line). Patients who had
previous toxicity on PVI 5-FU requiring early dose reduction
(within 4 weeks of starting treatment) started 5-FU at that reduced
dose. A maximum of 24 weeks of treatment was given. 
Antiemetic regimen included dexamethasone 8 mg and
granisetron 1 mg both as bolus intravenous injection prior to each
oxaliplatin administration. In addition metoclopromide 20 mg 4
times per day for 3 days and dexamethasone 4 mg 3 times per day
for 2 days orally were given after each oxaliplatin administration. 
Dose modification 
Toxicities were assessed according to National Cancer Institute-
Common Toxicity Criteria (NCI-CTC) version 1 (Macdonald et al,
1995). If thrombocytopenia or leucopenia > grade 3 developed
during the study, oxaliplatin was delayed until recovery and
reduced to 80 mg m–2 on subsequent cycles of treatment. PVI 5-
FU was stopped if grade 4 thrombocytopenia or neutropenia
occurred. Oxaliplatin was reduced to 80 mg m–2 on subsequent
cycles of treatment if grade 2 neuropathy occurred. If ≥ grade 3
neuropathy was encountered, oxaliplatin would be discontinued. 
If stomatitis, hand–foot syndrome or diarrhoea relating to 5-FU
developed, 50 mg m–2, 100 mg m–2 and 150 mg m–2 dose reduc-
tions were made to 5-FU if grade 2, 3 and 4 toxicities developed
respectively. Chemotherapy was discontinued in the events of
disease progression after a minimum of 4 weeks’ treatment or
intolerable toxicity. 
Study parameters 
Toxicity assessment, physical examination, complete blood count,
renal and liver function tests were performed before each cycle.
Tumour-related symptoms were assessed with a 15-point checklist
at baseline and at each hospital visit for patients who had these
symptoms on entry into the study. Disappearance or attenuation of
these tumour-related symptoms was recorded at each hospital
visit. CEA was measured at least once every 8 weeks. A reduction
in CEA concentration was considered a biological effect in
patients whose CEA levels had been elevated at baseline, but was
not used to evaluate response. Antitumour activity was evaluated
according to World Health Organisation (WHO) criteria (Miller
et al, 1981). CT scans of thorax, abdomen and pelvis were
repeated every 4 cycles or earlier in cases of clinical deterioration.
External review and confirmatory CT scans were not performed. 
Complete response (CR) was defined as the complete disap-
pearance of all measurable lesions, without the appearance of new
lesion(s). Partial response (PR) was defined as a reduction of bidi-
mensional lesions by ≥ 50% of the sum of the products of the
largest perpendicular diameters of each measurable lesion and no
progression in other lesions or the appearance of any new lesions.
Stable disease (SD) was defined as a < 50% reduction of tumour
volume or a less than 25% increase of the volume of one or more
measurable lesions, with no new lesions. Progressive disease (PD)
was defined as an increase of ≥ 25% of the size of at least one bidi-
mensionally measurable lesion, the appearance of new lesion(s),
and/or the onset of ascites or pleural effusion with cytological
confirmation. 
Statistical considerations 
Gehan’s 2-stage design was employed for estimating the response
rate. The sample size calculation was based on the double require-
ment of being able to stop the study early if the response rate was
lower than 20% and of estimating the response rate with a standard
error of < 0.1, power 95%. During the first stage of the design
comprising the first 14 patients, at least 4 responses were found.
We therefore proceeded to the second stage when response could
then be estimated with a standard error of < 0.1, power 95%. 
Failure-free survival and overall survival were estimated using
the Kaplan–Meier method from the start of chemotherapy. All
endpoints were updated on 1 October, 2000. Failure-free survival1260 I Chau et al 
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was calculated from the date chemotherapy was started to the date
either disease progression or death was observed. Overall survival
was estimated from the date of chemotherapy started to the date of
death from any cause. All analyses were made on an intention-to-
treat basis. 
RESULTS 
From June 1997 to September 2000, 38 patients were enrolled into
the study. One patient did not have objective tumour response and
toxicity assessment because of rapidly progressive disease. This
patient was considered to have progressed from the date of starting
chemotherapy. She was included in the survival and tumour
response analyses on intention to treat basis. However, she was
excluded from toxicity analysis. 
One patient had performance status of 3 on entry, but was
included in all analyses. Median follow up of patients was 6.1
months. Their characteristics are shown in Table 1. Median age of
patients was 61 years. 45% of patients had more than 2 sites of
disease involvement with liver being the most commonly affected.
74% of patients had locally advanced or metastatic disease at the
time of diagnosis. 35 patients had elevated CEA on entry into the
study with 45% > 100 µ g l–1. 
10 patients had received 5-FU-based adjuvant chemotherapy in
the past. A majority of patients received oxaliplatin and PVI 5-FU
as third or subsequent lines of palliative chemotherapy. 22 patients
had previously received both 5-FU and irinotecan as palliative regi-
mens (see Table 2). Out of these 22 patients, 13 had progressive
disease while receiving irinotecan. 7 patients had a response dura-
tion  ≤ 3 months on irinotecan. One patient was intolerant to
irinotecan and one received mitomycin C in between irinotecan
and oxaliplatin. 
Toxicity 
The incidences of the main toxic effects per patient according to
NCI-CTC grades are listed in Table 3. 252 cycles were evaluated.
The median number of cycles administered per patient was 6.
Grade 3–4 neutropenia occurred in only 2.6% of patients without
any episodes of febrile neutropenia. The only significant
nonhaematological toxicities were lethargy (37.8%) and diarrhoea
(18.9%). More encouragingly, no grade 3/4 neurological deficit
was noted in any participant although all patients who developed a
mild degree of peripheral sensory neuropathy responded well to
dose reduction. Only 4 patients required dose reduction due to
neuropathy after a median of 3 courses of oxaliplatin. 4 patients
had Hickman line-related complications. They were all superficial
Hickman-line exit-site infections that responded to a course of oral
flucloxacillin. No other Hickman-line-related complications were
noted. 
There was a significant increase in serum creatinine with
OXAF treatment (paired-samples t-test  P = 0.001), but the
mean of maximum serum creatinine during treatment was only
103 µ mol l–1. Altogether 8 patients developed a rise in serum
creatinine above the upper limit of normal (ULN) during OXAF
treatment. Only 2 out of 8 patients developed grade 1 toxicity
(serum creatinine > 1.5 × ULN). Both of these episodes occurred
as terminal events on the dates of death for both patients.
Consequently, no dose delay or reductions due to renal dysfunc-
tion were necessary during the study. No patients were withdrawn
from the study due to intolerable toxicities. 
Tumour response 
The best achieved objective response rate (ORR) for all patients
was 29% (95% Confidence Interval (CI) = 15–46%). 11 partial
Table 1 Patients characteristics 
Number of patients included 38 
Median age 61 (19–75) 
Gender 
Male 24 
Female 14 
Primary tumour 
Colon 26 
Rectum 10 
Rectosigmoid junction 2 
Sites of metastasis 
Liver 27 
Lung 17 
Others 17 
Involved sites 
17  
2 14 
>2 17 
WHO performance status 
03  
1 22 
2 12 
31  
Disease status at first diagnosis 
Advanced disease 28 
Localised disease 10 
Elevated alkaline phosphatase 
> 1 × ULN* 20 
> 3 × ULN* 6 
Elevated CEA 
> 5 µ g l–1 35 
> 100 µ gl –1 17 
*ULN = upper limit of normal range. 
Table 2 Chemotherapy history 
Adjuvant chemotherapy (n = 10) 
Bolus e.g. NCCTGa regimen 7 
Infused 5-FU 3 
Lines of palliative chemotherapy 
Second line chemotherapyb 16 
≥ Third line chemotherapy 22 
Previous palliative chemotherapy regimens
Infused 5-FU alone 9 
5-FU/leucovorin bolus 5 
5-FU/leucovorin + experimental tumour vaccine 3 
Irinotecan 12 
Irinotecan/ (modified) de Gramont 5-FUc/leucovorin 6 
Irinotecan + raltitrexed 3 
Irinotecan + UFT 2 
aNCCTG = North Central Cancer Treatment Group regimen refers to bolus 5-
FU day 1–5 every 4 weeks. bTwo patients developed metastatic disease
during adjuvant 5-FU based treatment and their adjuvant therapy was
considered as their first palliative line of chemotherapy. cde Gramont 5-FU
regimen refers to bolus 5FU on day 1+2 followed by 24 hours’ infusion of 5-
FU on each day repeated every 14 days. Modified de Gramont 5-FU
regimen refers to bolus 5FU on day 1 only followed by 48 hours’ infusion of
5-FU repeated every 14 days. Oxaliplatin and PVI 5-FU in advanced colorectal cancer 1261
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responses and no complete responses were noted (see Table 4).
The median duration of response was 3.9 months. Even for
patients who had previously received both 5-FU and irinotecan
(n = 22), 27.3% had partial response with OXAF. 
Symptom response 
37 patients had symptoms on entry into the study. 25 patients had
pain, 10 had anorexia and 28 had lethargy. 64%, 70% and 17.9%
had symptomatic improvement after treatment respectively. 10
patients experienced weight loss prior to receiving OXAF and all
of them had weight stabilisation or weight gain following treat-
ment. 35 patients had elevated CEA on entry into study. There was
a statistically significant decrease in CEA with treatment (paired-
samples t-test P = 0.022). 
Survival 
The median failure-free survival was 4 months (see Figure 1). The
median overall survival was 9.1 months. The survival probability
at 6 months was 58.4% (95% CI = 38.7–73.7%), at 9 months was
39.4% (95% CI = 14.6–63.7%) and at 12 months was 0% (see
Figure 2). For patients who had received both irinotecan and 5-FU
(n = 22), the median survival was 6 months. The survival proba-
bility at 6 months was 47.9% (95% CI = 23–69.2%). 
Dose intensity 
Oxaliplatin 
Eight patients (21%) had dose reductions in oxaliplatin during the
study. Only one patient required more than one dose reduction due
to toxicity (persistent thrombocytopenia). Therefore 97% of
patients had ≥ 80% of the intended dose of oxaliplatin. 
PVI 5-FU 
31 patients (82%) started 5-FU at 300 mg m–2 day–1, 22 (58%)
patients required dose reduction during the study. The median dose
of 5-FU on finishing treatment was 225 mg m–2 day–1. 20 out of 31
patients starting at 300 mg m–2 day–1 required dose modification 
DISCUSSION 
With the introduction of new drugs such as irinotecan and oxali-
platin in metastatic CRC in the last decade, oncologists now have
an improved armoury against this second most common cancer
killer in the Western world. However oxaliplatin has a limited
single agent activity against metastatic colorectal carcinoma
(Machover et al, 1996) and the challenge remains to determine the
optimal dose and schedule of oxaliplatin in combination with 5-
FU and other drugs such as oral fluoropyrimidines (Zeuli et al,
2000; Cunningham and James, 2001), irinotecan (Wasserman et al,
1999; Goldwasser et al, 2000; Gornet et al, 2000; Hejna et al,
2000) and other TS inhibitors (Douillard et al, 2000; Fizazi et al,
2000; Scheithauer et al, 2001). Several phase II and III studies
have confirmed the activity of oxaliplatin and 5-FU with folinic
acid either as constant (Levi et al, 1994; Andre et al, 1999;
Maindrault-Goebel et al, 1999) or chronomodulated continuous
infusion (Levi et al, 1994, 1997, 1999; Giacchetti et al, 2000). 2
studies reported on the use of oxaliplatin and protracted venous
infusion of 5-FU. Martoni et al recently reported a response rate of
22% in 50 patients who were treated with a 3-weekly schedule of
oxaliplatin and PVI 5-FU (Martoni et al, 2001). In this study,
patients were treated at 4 dose levels employing 2 different doses
of oxaliplatin and 2 doses of 5-FU. The authors suggested the
optimum dose level of oxaliplatin should be 130 mg m–2 every 3
weeks and PVI 5-FU should be 250 mg m–2 day–1. Only 16 patients
were treated at this optimum dose, although a higher response rate
(37.5%) was achieved. Interestingly, for patients who had received
2 or more lines of antitumour treatment in this study, only one
responder was seen. In another study, Adenis et al reported a
36.7% response rate using a 3-weekly schedule of oxaliplatin 130
mg m–2 and 5-FU 250 mg m–2 day–1 in a phase II–III study
Table 3 Toxicity profile 
Side effects NCI-CTC* grade (%) 
01 2 34
Diarrhoea 29.7 18.9 32.4 10.8 8.1 
Stomatitis 62.2 24.3 10.8 2.7 0 
Nausea and vomiting 24.3 43.2 29.7 2.7 0 
Alopecia 64.9 16.2 18.9 0 0 
Peripheral neuropathy 0 66.7 33.3 0 0 
Palmar plantar erythema 62.2 21.6 16.2 0 0 
Infection 64.9 10.8 18.9 5.4 0 
Fever 83.8 2.7 10.8 2.7 0 
Lethargy 0 8.1 54.1 37.8 0 
Anaemia 36.8 10.5 42.1 5.3 5.3 
Neutropenia 71.1 18.4 7.9 2.6 0 
Thrombocytopenia 55.3 21.1 18.4 2.6 2.6 
*NCI-CTC = National Cancer Institute-Common Toxicity Criteria. All 38 patients
assessable for haematological toxicities. 37 assessable for non-haematological toxicities. 
Table 4 Disease response 
Response Number of  % of patients 
patients (n = 38)
Complete response 0 0 
Partial response 11 28.9 
Stable disease 20 52.6 
Progressive disease 7 18.4 1262 I Chau et al 
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Figure 1 The median failure-free survival was 4 months
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comparing this regimen with either PVI 5-FU or irinotecan
(Adenis et al, 2000). Final results of the second study are awaited. 
Our study has confirmed that OXAF was an active and safe
regimen. In particular, our cohort of patients had a heavy tumour
burden and had been heavily pre-treated before. 82% of patients
had 2 or more sites of metastasis on entry into study. All but 3 had
elevated CEA. Moreover, over half of patients received OXAF as
third or subsequent lines of palliative chemotherapy with 22
patients received prior fluoropyrimidines and irinotecan chemo-
therapy either in combination or in sequential fashion. 
Despite these adverse factors, a response rate of 29% was still
achieved which compared favourably with other second-line
studies in advanced CRC using oxaliplatin, 5-FU and leucovorin.
Furthermore, another 53% achieved stable disease. Disease stabil-
isation is clinically meaningful as quality of life benefits have been
shown in those in whom the disease is stabilised (Glimelius et al,
1994; Allen et al, 1998; Van Cutsem et al, 1999). Other studies
have shown that stabilisation of progressive CRC was associated
with both prolonged survival and subjective improvement (Allen
et al, 1998). In our cohort of patients, over 80% of patients had
control of tumour growth from receiving OXAF and might there-
fore have derived clinical benefit. This was further evidenced by
the high proportion of patients who obtained symptomatic
improvement following treatment in the study. Moreover, the
survival rate in our study is comparable to other second line
studies using either oxaliplatin or irinotecan based chemotherapy
(Cunningham et al, 1998; Rougier et al, 1998; Andre et al, 1999;
Brienza et al, 1999; Maindrault-Goebel et al, 1999]. 
The encouraging results from our study may be explained by the
fact that nearly 80% of patients had full intended dose of oxali-
platin. Another encouraging observation was the relatively high
response rate after both 5-FU and irinotecan failures. Few
published studies have reported activity of oxaliplatin after
irinotecan failure and the relatively high response rate demon-
strated non-cross resistance of these 2 useful drugs in advanced
CRC. As the patient number in this subgroup of our study was
small (n = 22), the confidence interval of survival is understand-
ably large. Therefore the true survival effect after irinotecan
failure cannot be determined in our study. 
Treatment-related toxicity during this study was mild and infre-
quent. No patients were withdrawn from the study due to intoler-
able toxicities. No functional neurological deficit was noted
which was commonly the reason of patient withdrawal or dose
reduction in other studies using oxaliplatin (Andre et al, 1999;
Levi et al, 1999; Maindrault-Goebel et al, 1999; Giacchetti et al,
2000). Of the 8 patients that required dose reduction in oxaliplatin
during the study, 4 did so because of persistent grade 2 peripheral
neuropathy in-between courses. However all improved after dose
adjustment and no further dose reductions were required. Severe
dose-limiting peripheral sensory neuropathy (grade 3/4) normally
occurs in 10% to 15% of patients after a total cumulative dose of
780 to 850 mg m–2 of oxaliplatin (Armand et al, 2000). As the
median number of oxaliplatin courses in our study was 6 giving a
cumulative dose of 600 mg m–2, this may have explained the low
incidence of peripheral sensory neuropathy. There was a statisti-
cally significant deterioration of renal function demonstrated by
increase in serum creatinine in participants during the study, but
the mean maximum serum creatinine after treatment was only 103
µ mol l-1. Since we have not directly measured glomerular filtra-
tion rate (GFR) during this study, the renal dysfunction demon-
strated did not appear to be clinically relevant. Pharmacokinetic
studies in 5-FU and oxaliplatin indicated no significant interac-
tions occurred between these 2 drugs (Misset and Allain, 1995;
Papamichael et al, 1998). Moreover glomerular filtration is the
principal mechanism of platinum clearance after oxaliplatin
administration and the renal clearance of ultrafilterable platinum
has been shown to be significantly correlated with GFR (Graham
et al, 1999, 2000). Glomerular filtration rate measurement would
therefore be a more accurate assessment of renal toxicity from
oxaliplatin administration. 
Incidences of grade 3/4 haematological toxicity, especially
neutropenia, during this study were infrequent compared to other
studies (Andre et al, 1999; Levi et al, 1999; Maindrault-Goebel
et al, 1999; de Gramont et al, 2000; Giacchetti et al, 2000) consid-
ering many patients have been heavily pre-treated. This is presum-
ably due to the nonmyelosuppressive nature of PVI 5-FU. The
only significant 5-FU-related toxicity was diarrhoea. Nearly two
thirds of participants required some dose reduction of 5-FU during
our study with a starting dose of 300 mg m–2 day–1. Therefore a
starting dose of 250 mg m–2 day–1 could be considered in this
biweekly oxaliplatin regimen especially in patients who have
previously developed early toxicity to 5-FU. 
In conclusion oxaliplatin and PVI 5-FU is an active and well-
tolerated regimen in patients with heavily pre-treated advanced
colorectal cancer. Furthermore, OXAF remains a viable and attrac-
tive option after irinotecan failure. This regimen should be further
evaluated in both first-and second-line settings. 
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